Nicolas Girard - splf.frsplf.fr/wp-content/uploads/2016/09/GOLFTHY5.pdf · Les tumeurs du thymus...
-
Upload
truongnhan -
Category
Documents
-
view
216 -
download
0
Transcript of Nicolas Girard - splf.frsplf.fr/wp-content/uploads/2016/09/GOLFTHY5.pdf · Les tumeurs du thymus...
Lestumeurs duthymus
NicolasGirardInstitut deCancérologie desHospicesCivilsdeLyon
Lyon,France
Liensd’intérêt
Jesuis coordonateur adjoint duréseau RYTHMIC.
Jenesuis pasmembre ducomité destagingdel’IASLC.
Jenesuis pasmembre ducomité depublicationdel’ITMIG.
Jesuis consultantpourleslaboratoires BMS,MSD,Novartis,Pfizer.
2016
Tumeurs thymiques
Tumeurs thymiques
• Incidence:0,15-0,30/100000people
• 250casesinFrance/year
Engelsetal.IntJCancer2003;105:546InstitutNationalduCancer,e-cancer.fr
Prostate70000
Breast55000Colo-rectal
41000Hodgkin1800
Mesothélioma800
GIST900
Melanoma10000 LUNG
40000
Thymomas250
Retinoblastoma100
TETs are rare malignancies with an overall incidence of 0.13 per 100.000 person-years. Given this, most of our knowledge is largely derived from small single-institution series.
RYTHMIC (Réseau tumeurs THYMiques et Cancer) is a French network for TET created by INCa (French National Cancer Institute) with the objective of territorial coverage by 14regional expert centers, systematic discussion of patients at national tumor board and collection of nationwide data within a centralized database. OBJECTIVE: We reviewed our
activity in 2016 in order to describe the epidemiology and main characteristics at diagnosis of Tumeurs thymiquesin France.
BACKGROUND AND OBJECTIVE
B
C
A
B
The estimated incidence of TETS in France in 2016 is 0.34 per 100.000 persons, based on our
activity. The inclusion in the RYTHMIC network is mandatory but is still based on physician’srequest. Although we might underestimate the incidence, it seems to be higher compared to
other countries’ registries. The high occurrence of previous cancer might underlie variations in
environmental or genetic risk factors.
A
PATIENTS AND METHODS
RESULTS
CONCLUSION
-We prospectively collected all patients (pts) with new diagnosis of primary TET in France discussed at national or regional RYTHMIC tumor board from January to December 2016.
-Epidemiologic, clinical, pathologic and surgical data were prospectively collected within a centralized database.-Histologic sub-type was centrally reviewed according to the WHO classification and stage by modified Masaoka-Koga classification.
-Fisher exact test was used for correlations.
Bluthgen MV1, Dansin E2, Kerjouan M3, Mazieres J4, Pichon E5, Thillays F6, Massard G7, Quantin X8, Oulkhouir Y9, Westeel V10, Thiberville L11, Clement-Duchene C12, Thomas P13, Girard N14, Besse B1
1 Gustave Roussy, Villejuif, France; ²Oscar Lambret, Lille, France; ³Centre Hospitalier Universitaire de Rennes, Rennes, France; 4Centre Hospitalier Universitaire de Tolouse, Tolouse, France; 5Hôpital Bretonneau, Tours, France; 6Institut de Cancérologie de l’ouest, Rouen, France; 7Centre Hospitalier Universitaire de Strasbourg, Strasbourg, France; 8Centre Hospitalier Universitaire de Montpellier, Montpellier, France; 9Centre Hospitalier Universitaire de Caen, Caen, France; 10Centre Hospitalier Universitaire de Besancon, Besancon, France; 11Centre Hospitalier Universitaire de Rouen, Rouen, France; 12Centre Hospitalier Universitaire de Nancy, Nancy,
France; 13Hôpital Nord, Marseille, France; 14Hôpital Louis Pradel, Lyon, France
Updated incidence of Thymic Epithelial Tumors (TET) in France and clinical presentation at diagnosis
UK: unknown; CAP: cisplatin, doxorubicin,cyclophosphamide; VIP: cisplatin, etoposide,ifosfamide.
Patient’s characteristics and treatment
Frequencyn=226 (%)
Primary treatmentUpfront SurgeryNeo-adjuvant chemotherapy ChemotherapyAdjuvant radiotherapy
170 (75)8 (3)
40 (18)55 (24)
Surgery ApproachSternotomyVideothoracoscopyRobot assisted ThoracotomyOther
178 (100)108 (61)37 (21)15 (8)9 (5)9 (5)
ChemotherapyCAPCarboplatin-paclitaxelCarboplatin-etoposide
33 (63)16 (31)3 (6)
Frequency n=226 (%)
Age Median [range] 62 [25 – 86]
GenderMaleFemale
129(57)97(43)
Auto-inmune disorderMyastheniaAnemiaThyroiditisHypogammaglobulinemiaOthers
46 (20)353224
Previous cancerProstateBreastMelanomaHematologicOther
34 (15)974211
Mode of diagnosisResectionSurgical biopsyImaging guided biopsy
158 (70)35 (15)33 (15)
A. Observed incidence of TET in France (per 100.000-person-year) according to gender.*Based on INSEE (Institut National de la Statistique et des Etudes Economiques) populationdata registries according to gender for France 2016. B. Age-specific incidence of thymoma:observed values for thymoma incidence (per 100,000 person-years) plotted in function of age.
Significant correlations were found between histologic sub-type (Thymomavs. Thymic carcinoma) and presence of an autoimmune disorder (p=0.01)and stage (I-II vs. III-IV, p=0.004); no significant correlations were seen withgender (p=0.27)
0,00
5,00
25 75
MenB. Age-specific incidence of TET
Distribution of stage (Masaoka-Koga ITMIG modified) and histology (WHO2004 classification).
TETs are rare malignancies with an overall incidence of 0.13 per 100.000 person-years. Given this, most of our knowledge is largely derived from small single-institution series.
RYTHMIC (Réseau tumeurs THYMiques et Cancer) is a French network for TET created by INCa (French National Cancer Institute) with the objective of territorial coverage by 14regional expert centers, systematic discussion of patients at national tumor board and collection of nationwide data within a centralized database. OBJECTIVE: We reviewed our
activity in 2016 in order to describe the epidemiology and main characteristics at diagnosis of Tumeurs thymiquesin France.
BACKGROUND AND OBJECTIVE
B
C
A
B
The estimated incidence of TETS in France in 2016 is 0.34 per 100.000 persons, based on our
activity. The inclusion in the RYTHMIC network is mandatory but is still based on physician’srequest. Although we might underestimate the incidence, it seems to be higher compared to
other countries’ registries. The high occurrence of previous cancer might underlie variations in
environmental or genetic risk factors.
A
PATIENTS AND METHODS
RESULTS
CONCLUSION
-We prospectively collected all patients (pts) with new diagnosis of primary TET in France discussed at national or regional RYTHMIC tumor board from January to December 2016.
-Epidemiologic, clinical, pathologic and surgical data were prospectively collected within a centralized database.-Histologic sub-type was centrally reviewed according to the WHO classification and stage by modified Masaoka-Koga classification.
-Fisher exact test was used for correlations.
Bluthgen MV1, Dansin E2, Kerjouan M3, Mazieres J4, Pichon E5, Thillays F6, Massard G7, Quantin X8, Oulkhouir Y9, Westeel V10, Thiberville L11, Clement-Duchene C12, Thomas P13, Girard N14, Besse B1
1 Gustave Roussy, Villejuif, France; ²Oscar Lambret, Lille, France; ³Centre Hospitalier Universitaire de Rennes, Rennes, France; 4Centre Hospitalier Universitaire de Tolouse, Tolouse, France; 5Hôpital Bretonneau, Tours, France; 6Institut de Cancérologie de l’ouest, Rouen, France; 7Centre Hospitalier Universitaire de Strasbourg, Strasbourg, France; 8Centre Hospitalier Universitaire de Montpellier, Montpellier, France; 9Centre Hospitalier Universitaire de Caen, Caen, France; 10Centre Hospitalier Universitaire de Besancon, Besancon, France; 11Centre Hospitalier Universitaire de Rouen, Rouen, France; 12Centre Hospitalier Universitaire de Nancy, Nancy,
France; 13Hôpital Nord, Marseille, France; 14Hôpital Louis Pradel, Lyon, France
Updated incidence of Thymic Epithelial Tumors (TET) in France and clinical presentation at diagnosis
UK: unknown; CAP: cisplatin, doxorubicin,cyclophosphamide; VIP: cisplatin, etoposide,ifosfamide.
Patient’s characteristics and treatment
Frequencyn=226 (%)
Primary treatmentUpfront SurgeryNeo-adjuvant chemotherapy ChemotherapyAdjuvant radiotherapy
170 (75)8 (3)
40 (18)55 (24)
Surgery ApproachSternotomyVideothoracoscopyRobot assisted ThoracotomyOther
178 (100)108 (61)37 (21)15 (8)9 (5)9 (5)
ChemotherapyCAPCarboplatin-paclitaxelCarboplatin-etoposide
33 (63)16 (31)3 (6)
Frequency n=226 (%)
Age Median [range] 62 [25 – 86]
GenderMaleFemale
129(57)97(43)
Auto-inmune disorderMyastheniaAnemiaThyroiditisHypogammaglobulinemiaOthers
46 (20)353224
Previous cancerProstateBreastMelanomaHematologicOther
34 (15)974211
Mode of diagnosisResectionSurgical biopsyImaging guided biopsy
158 (70)35 (15)33 (15)
A. Observed incidence of TET in France (per 100.000-person-year) according to gender.*Based on INSEE (Institut National de la Statistique et des Etudes Economiques) populationdata registries according to gender for France 2016. B. Age-specific incidence of thymoma:observed values for thymoma incidence (per 100,000 person-years) plotted in function of age.
Significant correlations were found between histologic sub-type (Thymomavs. Thymic carcinoma) and presence of an autoimmune disorder (p=0.01)and stage (I-II vs. III-IV, p=0.004); no significant correlations were seen withgender (p=0.27)
0,00
5,00
25 75
MenB. Age-specific incidence of TET
Distribution of stage (Masaoka-Koga ITMIG modified) and histology (WHO2004 classification).
Specificities
2016
Tumeurs thymiques
Specificities- Thymic origin
2016
Tumeurs thymiques
Thethymus
Thymus
Celluleépithélialemédullaire
Celluledendritique
Apoptose
ToléranceimmunitaireAuxantigènesdusoi
Délétionclonale
Lymphocyteimmature
Thymus
Celluleépithélialemédullaire
Celluledendritique
Apoptose
ToléranceimmunitaireAuxantigènesdusoi
Délétionclonale
Lymphocyteimmature
Thymus
Celluleépithélialemédullaire
Celluledendritique
Apoptose
ToléranceimmunitaireAuxantigènesdusoi
Délétionclonale
Lymphocyteimmature
Sélection positivedeslymphocytes
Celluleépithélialemédullaire
Celluledendritique
Apoptose
ToléranceimmunitaireAuxantigènesdusoi
Délétionclonale
Celluleépithélialethymique
CORTEX
Lymphocyteimmature
Celluleépithélialethymique
MEDULLACelluledendritique
Apoptose
ToléranceimmunitaireAuxantigènesdusoi
Délétionclonale
Lymphocyteimmature
Sélectionnégativedeslymphocytes
Mathisetal.AnnuRevImmunol2009;27:287
Celluledendritique
Apoptose
ToléranceimmunitaireAuxantigènesdusoi
Délétionclonale
Lymphocyteimmature
Sélectionnégativedeslymphocytes
Celluleépithélialethymique
Mathisetal.AnnuRevImmunol2009;27:287
Apoptose
Celluledendritique
Apoptose
Toléranceimmunitaireaux antigènesdusoi
Délétionclonale
Lymphocyteimmature
Sélectionnégativedeslymphocytes
Celluleépithélialethymique
Mathisetal.AnnuRevImmunol2009;27:287
Apoptose
Celluledendritique
Apoptose
ToléranceimmunitaireAuxantigènesdusoi
Délétionclonale
Lymphocyteimmature
Sélectionnégativedeslymphocytes
Celluleépithélialethymique
Mathisetal.AnnuRevImmunol2009;27:287
Apoptose
Celluledendritique
Apoptose
ToléranceimmunitaireAuxantigènesdusoi
Délétionclonale
Lymphocyteimmature
Celluleépithélialethymique
Sélectionnégativedeslymphocytes
Mathisetal.AnnuRevImmunol2009;27:287
Apoptose
Specificities- Thymic origin- Complexhistology
2016
Tumeurs thymiques
• WorldHealthOrganization2016
A AB B1 B2 B3
“Médullary” Mixed “Cortical”
Histo-pathologicclassification
SCC
Thymoma Carcinoma
Reproductibilité delaclassification?
• Reproductibilité imparfaite
- Variabilité delaproportiondechaque type
- Etudedereproductibilitéinter-observateur:k=0,45-0,49
Marchevsky etal.Cancer2008; 112:2780Rieker etal.Int JCancer2002;98:900;Verghese etal.Histopathology2008;53:218
Reproductibilité delaclassification?
• Reproductibilité imparfaite
- Hétérogénéité tumorale desthymomes detypeA
InternationalThymic MalignancyInterestGroup2011
Reproductibilité delaclassification?
• Reproductibilité imparfaite:
- Formes combinées :25%descas?- Formes frontières
InternationalThymic MalignancyInterestGroup2011
Thymome type B2 (n=22)
Thymome type A (n=8)
Thymome type B3 (n=8)
Carcinome thymique (n=7)
Genomicprofilingofthymic epithelialtumors
Girardetal.Clin CancerRes2009; 15:6790
• MSKCC,45patients
The2016 WHOclassification
Actualisation delaclassificationhisto-pathologique
Actualisation delaclassificationhisto-pathologique
Actualisation delaclassificationhisto-pathologique
Intérêt deladoublelectureanatomopathologique
Intérêt deladoublelectureanatomopathologique
Intérêt deladoublelectureanatomopathologique
Specificities- Thymic origin- Complexhistology- Auto-immunity
2016
Tumeurs thymiques
Celluledendritique
Apoptose
ToléranceimmunitaireAuxantigènesdusoi
Délétionclonale
Lymphocyteimmature
Celluleépithélialethymique
Sélectionnégativedeslymphocytes
Mathisetal.AnnuRevImmunol2009;27:287
Apoptose
Lesthymomesn’exprimentpasAIRE
Ströbeletal.JPathol2007;211:563
ExpressiondeAIRE(ARNm)dans 20thymomes (controle :thymussain).
Celluledendritique
Apoptose
Mathisetal.AnnuRevImmunol2009;27:287
Délétionclonale
Lymphocyteimmature
Manifestationsauto-immunes
Celluleépithélialethymiquetumorale
Délétionclonale
Auto-immunitéPasdedélétion
clonalePasd’apoptose
NeuromuscularMyastheniagravisPeripheralneuropathyPolymyositisDermatomyositisEncephalitisOpticalmyelitis
HaematologicdisordersRedcellaplasiaPerniciousanaemiaErythrocytosisPancytopoeniaHaemolyticanaemiaLeukaemiaMultiplemyeloma
Auto-immunedisordersSystemiclupuserythematosusRheumatoidarthritisSjogren’ssyndromeScleroderma
EndocrinedisordersMultipleendocrineneoplasiaCushing’ssyndromeThyrotoxicosisPneumonitis
DermatologicdisordersPemphigusLichenplanusChronicmucosalcandidiasisAlopeciaareata
MiscellaneousGiantcellmyocarditisNephroticsyndromeUlcerativecollitisHypertrophicosteoarthropathyInterstitialpneumonitis
ImmunedeficiencydisordersHypogammaglobulinaemiaT-celldeficiencysyndrome
Auto-immunedisorders
Syndromespara-thymiques
• Bilan minimalrecommandé encas desuspiciondemanifestationsauto-immunesassociées auxtumeurs thymiques
Rinaldietal.NeurolSci2009;30:237
• Causesofdeath:
Huangetal.JThorac Oncol 2010;5:2017
Prognosisofthymoma
Specificities- Thymic origin- Complexhistology- Auto-immunity- Staging 2016
Tumeurs thymiques
Masaoka-Kogastagingsystem
ClassificationMasaoka-Koga-ITMIG
Detterbecketal.JThorac Oncol 2011;6:S1710
• Classificationanatomo-clinique:pTNM
• Evaluableaprèsrésection chirurgicale
Stade I
Detterbecketal.JThorac Oncol 2011;6:S1710
Stade IIA
Detterbecketal.JThorac Oncol 2011;6:S1710
Stade IIB
Detterbecketal.JThorac Oncol 2011;6:S1710
Stade IIB
Detterbecketal.JThorac Oncol 2011;6:S1710
Stade III
Detterbecketal.JThorac Oncol 2011;6:S1710
Stade III
Detterbecketal.JThorac Oncol 2011;6:S1710
Stade IVA
Detterbecketal.JThorac Oncol 2011;6:S1710
Stade IVB
Detterbecketal.JThorac Oncol 2011;6:S1710
Masaoka-Kogastagingsystem
Surgicalpathologystaging
Noclinicalstaging
Thymic epithelialtumors:stageandhistology
WHO,2016
Regnard etal.JThorac Cardiovasc Surg 1996;112:376Mooreetal.AnnThorac Surg 2001;72:203
Gawrychowski etal,EurJ Surg Oncol 2000;26:203-8
PrognosticvalueoftheMasaoka stagingsystem
Specificities- Thymic origin- Complexhistology- Auto-immunity- Staging 2016
Tumeurs thymiques
InternationalThymic MalignancyInterestGroup
Masaoka-Koga :I,IIA,IIB,III
Masaoka-Koga :III
Masaoka-Koga :III
Masaoka-Koga :IVA,IVB Masaoka-Koga :IVB
• Causesofdeath:
Huangetal.JThorac Oncol 2010;5:2017
Prognosisofthymoma
Stage,Histology,Other?
• ThemostsignificantprognosticfactorinTumeurs thymiquesis thecompletionofsurgicalresection,whateverclassificationisused.
Rossietal.Histopathology2008;53:483
TreatmentofTumeurs thymiques
• Firstquestionis:resectable ornot?
NationalComprehensiveCancerNetworkGuidelines
TreatmentofTumeurs thymiques
• Firstquestionis:resectable ornot?
NationalComprehensiveCancerNetworkGuidelines
Specificities- Thymic origin- Complexhistology- Auto-immunity- Staging
Resectabletumors
2016
Tumeurs thymiques
• Lestumeursprimitivesdumédiastinantérieurontunaspectradiologiquesouventsimilaire
Diagnosticdifférentiel
Tératome
MaladiedeHodgkin
Tumeurgerminalenonséminomateuse
Thymome
Tumeurs médiastinales:signes cliniques
• Absencedetabagisme:80%destumeursmédiastinales
• Age<40ans:50%destumeursmédiastinales
JThorac Oncol 2014;9:S102
Specificities- Thymic origin- Complexhistology- Auto-immunity- Staging
Resectabletumors
2016
Tumeurs thymiques
Nécessitéd’unebiopsiepré-thérapeutique
• Lachirurgieestrecommandéed’embléepourcertainestumeursdumédiastin:- Tumeursbénignes:tératomes- Tumeurskystiques- Thymomesnoninvasifs/encapsulés/avecenvahissementlimité
Kesler etal.AnnThorac Surg 2008;85:371Kesler etal.ThorSurg Clin 2009;19:63
Lemarié etal.Chest1992;102:1477
Nécessitéd’unebiopsiepré-thérapeutique
• Lachirurgieestrecommandéed’embléepourcertainestumeursdumédiastin:- Tumeursbénignes:tératomes- Tumeurskystiques- Thymomesnoninvasifs/encapsulés/avecenvahissementlimité
• Lachimiothérapieestuneurgenceencasdetumeurgerminalemaligne:- silesmarqueurssontélevés:14-35%ofcases
- α-foeto-protéine>1000kUI/L- tumeurgerminalenonséminomateuse (sacvitellin)
- β-human chorionic gonadotrophin >5000kUI/L- tumeurgerminalenonséminomateuse (choriocarcinome)- rareencasdeséminome
Kesler etal.AnnThorac Surg 2008;85:371Kesler etal.ThorSurg Clin 2009;19:63
Lemarié etal.Chest1992;102:1477
Nécessitéd’unebiopsiepré-thérapeutique
• Lachirurgieestrecommandéed’embléepourcertainestumeursdumédiastin:- Tumeursbénignes:tératomes- Tumeurskystiques- Thymomesnoninvasifs/encapsulés
• Lachimiothérapieestuneurgenceencasdetumeurgerminalemaligne:- silesmarqueurssontélevés:14-35%ofcases
- α-foeto-protéine>1000kUI/L- tumeurgerminalenonséminomateuse (sacvitellin)
- β-human chorionic gonadotrophin >5000kUI/L- tumeurgerminalenonséminomateuse (choriocarcinome)- rareencasdeséminome
Kesler etal.AnnThorac Surg 2008;85:371Kesler etal.ThorSurg Clin 2009;19:63
Lemarié etal.Chest1992;102:1477
Dans tous lesautres cas
biopsie
Specificities- Thymic origin- Complexhistology- Auto-immunity- Staging
Resectabletumors
2016
Tumeurs thymiques
• CTscan:low-attenuation,symmetricandfattypattern,maintainingthebi-pyramidalshapeofthethymus
• “Rebound”hyperplasia:- stress:pneumonia,surgery,burns,corticoidtreatment- chemotherapy:
- 10-25%ofcases,youngadults,intensivetreatment
• Lymphoidhyperplasia- autoimmuneandinflammatorydisorders- connectivetissuediseasesandvasculitis- myasthenia
Hendrick etal.Rofo 1989:150:268;Miniero R.BoneMarrowTransplant.1993;11:67
Gerhardtetal.Dtsch MedWochenschr 2004;129:1916
Thymome ou hyperplasie thymique?
Thymome ou hyperplasie thymique?
• ELCAPlung cancerscreeningstudy:- forme ovoïdeettaille<3cm:hyperplasie
Henschke etal.Radiology 2006;23:239:586
Imagerie pré-thérapeutique
Kimar etal.AnnNucl Med2009;23:569Endoetal.LungCancer2008;61:350
- UtilisationduPET-scan:corrélationavecclassifications
Imagerie pré-thérapeutique
Igai etal.Eur JCardiothor Surg 2011;40:143Kimar etal.AnnNucl Med2009;23:569;Endoetal.LungCancer2008;61:350
Kaira etal.JClin Oncol 2011;28:3746;Shibataetal.Cancer2009;115:2531
- UtilisationduPET-scan:hyperplasie vs.thymomevs.carcinomethymique
T2WFS Inphase Opposedphase
Hyperplasie thymique
Specificities- Thymic origin- Complexhistology- Auto-immunity- Staging
Resectabletumors
2016
Tumeurs thymiques
JThorac Oncol 2011;6:1274 JThorac Oncol.2014;9:1023
Imagerie pré-thérapeutique
- Prédictionde l’invasivité parlatomodensitométrie:MDAnderson,99patients
Masaoka-Koga :I,IIA,IIB,III
Définition delarésécabilité
Specificities- Thymic origin- Complexhistology- Auto-immunity- Staging 2016
Tumeurs thymiques
- Surgery
Resectabletumors
• Mediansternotomy isthestandardapproach• Completeexplorationofthepleuralcavities
• Completethymectomy,including tumor,normalthymus,andmediastinal fat• enbloc resectionofinvolvedstructures:
- lung,vessels,pleuralimplants,phrenicnerves- surgicalclipsinareasofconcern
• Mediastinal notessampling/resection (stageIIItumor/thymic carcinoma)
• Frozensectionnotrecommendedformarginsassessment
Surgeryrecommendations
Orientationand markingintheoperativeroom
• Useofamediastinal board
Minimally-invasivesurgery?
Specificities- Thymic origin- Complexhistology- Auto-immunity- Staging 2016
Tumeurs thymiques
- Surgery- Postoperativeradiotherapy
Resectabletumors
StageIStageII-III
…butnobenefitaftercompleteresection
```` (p=0.12)
• Population: - thymomas andthymic carcinomas- 1973-2005,901patients:275stageI,626stageII-III
Postoperativeradiotherapy:SEERdatabase
Forquer etal.Int JRadiatOncol Biol Phys2008;76:440
Postoperativeradiotherapy:“meta-analysis”
• Inclusioncriteria:- studiespublishedfrom1981to2008- surgeryvs.surgery+radiotherapy- thymoma andthymic carcinoma- completeresection- stageIIandIII
• Results:- 13studies,542patients
- radiotherapy:250patients- noradiotherapy:342patients
- OR=1.05(0.63;1.75-0.84)onrecurrencerate
Korst etal.AnnThorac Surg 2009;87:1641
Postoperativeradiotherapy:ITMIGdatabase
Specificities- Thymic origin- Complexhistology- Auto-immunity- Staging 2016
Tumeurs thymiques
- Surgery- Postoperativeradiotherapy
Resectabletumors
68/143
20/37
0
20
40
60
80
100
0 5 10 15 20 25
Stage I/IIStage IIIStage IVAStage IVB
%
Years
Events/n 10-year recurrence % (IC95)121/3 097140/65464/10917/38
8 (7-8)29 (27-31)71 (34-100)57 (24-90)
0
20
40
60
80
100
0 5 10 15 20
Stage I/IIStage IIIStage IVAStage IVB
%
Years
28/112
19/26
25 (22-29)59 (44-76)
76 (58-100)54 (37-67)
Thymomas(n = 7 005)
Thymic carcinomas(n = 977)
Cumulativeincidenceofrecurrences inMasaoka-Koga groups
ITMIGretrospective database
Detterbecketal.WCLC2013,abstr.MS16.2
Recurrencerates
Events/n 10-year recurrence % (IC95)
Population: AllR0stageI,IIpts withrecurrenceoutcomeandWHOsubtypeinformation
RecurrencebyWHOHistology,R0,stageI,II
P<0.006forTCvs anyWHOtype
TC
B3
A AB
B2B1
}P=NS}P=NS
P<0.01
Weissetal.ITMIG2014
Specificities- Thymic origin- Complexhistology- Auto-immunity- Staging 2016
Tumeurs thymiques
- Surgery- Postoperativeradiotherapy
Resectabletumors
Girardetal.AnnOncol 2016;26:v40
Recommandations RYTHMICESMOClinicalPracticeGuidelines
Recommandations RYTHMICESMOClinicalPracticeGuidelines
Girardetal.AnnOncol 2016;26:v40
Girardetal.AnnOncol 2016;26:v40
Recommandations RYTHMICESMOClinicalPracticeGuidelines
Girardetal.AnnOncol 2016;26:v40
Recommandations RYTHMICESMOClinicalPracticeGuidelines
Girardetal.AnnOncol 2016;26:v40
Recommandations RYTHMICESMOClinicalPracticeGuidelines
Girardetal.AnnOncol 2016;26:v40
Recommandations RYTHMICESMOClinicalPracticeGuidelines
Girardetal.AnnOncol 2016;26:v40
Recommandations RYTHMICESMOClinicalPracticeGuidelines
Girardetal.AnnOncol 2016;26:v40
Recommandations RYTHMICESMOClinicalPracticeGuidelines
Girardetal.AnnOncol 2016;26:v40
Recommandations RYTHMICESMOClinicalPracticeGuidelines
Specificities- Thymic origin- Complexhistology- Auto-immunity- Staging 2016
Tumeurs thymiques
- Surgery- Postoperativeradiotherapy
Resectabletumors
Unresectabletumors
• Critèresd’inclusiondanslesessaisencours
- Diamètre supérieur à 8cm
- Diamètre compris entre5et8cm,avecl’un descritères suivants:- calcificationmultifocale- apparence hétérogène- bords irréguliers- invasionou engainement vasculaire
- Diamètre inférieur à 5cmetinvasionou engainement vasculaire
Tumeur thymiques localement avancée
NCT00387868(PI:R.Korst)
Définition delanon-résécabilité?
Masaoka-Koga :III
Specificities- Thymic origin- Complexhistology- Auto-immunity- Staging 2016
Tumeurs thymiques
- Surgery- Postoperativeradiotherapy
Resectabletumors
Unresectabletumors
- Primarychemotherapy
Locally-advancedtumors:multimodaltreatment
NationalComprehensiveCancerNetworkGuidelines
Pre-operativechemotherapy
Responserate80%
GirardN.Eur Respir Rev2013;22:75
Parketal,2013CDDP-Doc27T/TCIII/IVPhaseII 63
Responserate80%
Chimiothérapie pré-opératoire
GirardN.ASCO2012EducationalBookParketal.JThorac Oncol 2013;8:959
Parketal,2013CDDP-Doc27T/TCIII/IVPhaseII63
Enpratique:
CAP2+2cycles
CAP65%
CarboplatinPaclitaxel
16%
PE4%
VIP3%
Etoposide3% Other/Unk
nown9%
Proposedregimens
n=149
Administeredregimens
n=91
CAP76%
Paclitaxel+…
Etoposide+/- Platin
8%
Others6%
RYTHMIC:Chimiothérapie d’induction
MerveilleuxduVignaux,etal.ITMIG2016
Administeredregimens
n=91
CAP76%
Paclitaxel+…
Etoposide+/- Platin
8%
Others6%
RYTHMIC:Chimiothérapie d’induction
MerveilleuxduVignaux,etal.ITMIG2016
Administeredregimens
n=91
CAP76%
Paclitaxel+…
Etoposide+/- Platin
8%
Others6%
2%
28% 31%42%
25%15%17%
36%42%
44%71%
54%
77%
36% 19%
13%4%
31%
4% 7%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Primary Exclusive Recurrence1 Recurrence2 Recurrence3 Recurrence4
Progression
Stable
PartialresponseCompleteresponse
2%
28% 31%42%
25%15%17%
36%42%
44%71%
54%
77%
36% 19%
13%4%
31%
4% 7%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Primary Exclusive Recurrence1 Recurrence2 Recurrence3 Recurrence4
Progression
Stable
PartialresponseCompleteresponse
Tumorresponse
RYTHMIC:Chimiothérapie d’induction
MerveilleuxduVignaux,etal.ITMIG2016
Administeredregimens
n=91
CAP76%
Paclitaxel+…
Etoposide+/- Platin
8%
Others6%
2%
28% 31%42%
25%15%17%
36%42%
44%71%
54%
77%
36% 19%
13%4%
31%
4% 7%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Primary Exclusive Recurrence1 Recurrence2 Recurrence3 Recurrence4
Progression
Stable
PartialresponseCompleteresponse
2%
28% 31%42%
25%15%17%
36%42%
44%71%
54%
77%
36% 19%
13%4%
31%
4% 7%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Primary Exclusive Recurrence1 Recurrence2 Recurrence3 Recurrence4
Progression
Stable
PartialresponseCompleteresponse
TumorresponseRecurrence-free
survival
Median:20.7months
RYTHMIC:Chimiothérapie d’induction
MerveilleuxduVignaux,etal.ITMIG2016
Specificities- Thymic origin- Complexhistology- Auto-immunity- Staging 2016
Tumeurs thymiques
- Surgery- Postoperativeradiotherapy
Resectabletumors
Unresectabletumors
- Primarychemotherapy- Surgery
Treatmentofthymic tumors
• Locallyadvancedtumors:primarychemotherapy
NationalComprehensiveCancerNetworkGuidelines
Pre-operativechemotherapy
Responserate80%Complete
resection50%
(14-78%)
GirardN.Eur Respir Rev2013;22:75
Parketal,ASCO2012CDDP-Doc27T/TCIII/IV70 63425
Chirurgie destumeurs destade IVA
Pleuralchemo-hyperthermia
Specificities- Thymic origin- Complexhistology- Auto-immunity- Staging 2016
Tumeurs thymiques
- Surgery- Postoperativeradiotherapy
Resectabletumors
Unresectabletumors
- Primarychemotherapy- Surgery- postoperativetreatment
Recommandations RYTHMICESMOClinicalPracticeGuidelines
Specificities- Thymic origin- Complexhistology- Auto-immunity- Staging 2016
Tumeurs thymiques
- Surgery- Postoperativeradiotherapy
Resectabletumors
Unresectabletumors
- Primarychemotherapy- Surgery- postoperativetreatment
- Definitiveradiotherapy
Treatmentofthymic tumors
• Locallyadvancedtumors:primarychemotherapy
NationalComprehensiveCancerNetworkGuidelines
Chimio-radiothérapie exclusive
Responserate80%20-30%of
patients
GirardN.Eur Respir Rev2013;22:75
Parketal,ASCO2012CDDP-Doc27T/TCIII/IV70 63425
Definitivechemo-radiotherapyforthymomas
• Limiteddataintheliterature…noconsensus
- Sequentialapproach:- 23patients,stageIII-IVunresectable thymoma- inductionwithCAP(4cycles),thenradiotherapy- 5-yearPFS:54%- 5-yearOS:53%
- Concurrentapproach:Loehrer etal.JClin Oncol 1997;15:3093
Korst etal.JThorac Cardiovasc Surg 2014;147:36
Loehrer,JClin Oncol 1997;15:3093
Kitamietal.Jpn JClin Oncol 2001;31:601Nakamuraetal.Jpn JClin Oncol 2000;30:385
Stades localement avancés:chimio-radiothérapie
Enpratique:
Réponse partielle:radiothérapie séquentielle
Progression/stabilisation (B2-B3):radio-chimiothérapie concomitante
Specificities- Thymic origin- Complexhistology- Auto-immunity- Staging 2016
Tumeurs thymiques
- Surgery- Postoperativeradiotherapy
Resectabletumors
Unresectabletumors
- Primarychemotherapy- Surgery- postoperativetreatment
- Definitiveradiotherapy
Metastatictumors
- First-linechemotherapy
Palliative-intentchemotherapy
chemotherapy
NationalComprehensiveCancerNetworkGuidelines
Palliative-intentchemotherapyregimens
GirardN.ASCO2012EducationalBook
Anthracyclin-basedResponse:70-80%
Non-anthracyclin-basedResponse:30-50%
Palliative-intentchemotherapyregimens
GirardN.ASCO2012EducationalBook
Carboplatine-Paclitaxel
0%
20%
40%
60%
80%
100%
Lemman=21
Currentstudyn=13
Lemman=23
Hirain=39
Currentstudyn=27
Progression
Stabledisease
Objectiveresponse
Thymoma
Thymoma
Thymiccarcinoma
Thymic carcinoma
- Reproductibleresults
- Anewstandardforthymic carcinomas?
- Dowe need atrialofplatine-paclitaxel vs.CAP?
0 5 10 15 20
Lemman=23
Hirain=39
Currentstudyn=27
Lemman=21
Currentstudyn=13
PFS(months)
AnthracyclinesRéponse:70-80%
SansanthracyclinesRéponse:30-50%
GirardN.ASCO2012EducationalBook
Stades avancés ou métastatiques
Enpratique
Premièreligne:CAP
Carboplatine-Paclitaxel
4-6cycles
Kirkove Cetal.Clin Oncol 1992;4:64
Corticosteroidsandthymomas
•Depletionofthelymphocyticpopulation- “thymolytic effect”
•Steroidreceptorsin83%ofthymomas
•TumorresponsesreportedintypeBthymomas- 18cases,mixedthymoma:10partial
responses,4completeresponses- responsemaybeprolonged>12months- re-responsemaybeprolonged
•Specificities:- opportunisticinfections- increasedriskofmyasthenic crisis
Cravenetal.MuscleNerve1981;4:425Mimae etal.Cancer2011;117:4396
RYTHMIC:Exclusive(first-line)chemotherapy
CAP35%
CarboplatinPaclitaxel
32%
PE19%
VIP3%
Other/Unknown11%
Proposedregimens
n=37
Administeredregimens
n=41
CAP66%
Paclitaxel+
Carboplatin20%
Etoposide+/- Platin
12%
Others2%
Administeredregimens
n=41
CAP66%
Paclitaxel+Carboplatin
20%
Etoposide+/- Platin
12%
Others2%
RYTHMIC:Exclusive(first-line)chemotherapy
Administeredregimens
n=41
CAP66%
Paclitaxel+Carboplatin
20%
Etoposide+/- Platin
12%
Others2%
2%
28% 31%42%
25%15%17%
36%42%
44%71%
54%
77%
36% 19%
13%4%
31%
4% 7%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Primary Exclusive Recurrence1 Recurrence2 Recurrence3 Recurrence4
Progression
Stable
PartialresponseCompleteresponse
2%
28% 31%42%
25%15%17%
36%42%
44%71%
54%
77%
36% 19%
13%4%
31%
4% 7%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Primary Exclusive Recurrence1 Recurrence2 Recurrence3 Recurrence4
Progression
Stable
PartialresponseCompleteresponse
2%
28% 31%42%
25%15%17%
36%42%
44%71%
54%
77%
36% 19%
13%4%
31%
4% 7%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Primary Exclusive Recurrence1 Recurrence2 Recurrence3 Recurrence4
Progression
Stable
PartialresponseCompleteresponse
Tumorresponse
RYTHMIC:Exclusive(first-line)chemotherapy
Administeredregimens
n=41
CAP66%
Paclitaxel+Carboplatin
20%
Etoposide+/- Platin
12%
Others2%
2%
28% 31%42%
25%15%17%
36%42%
44%71%
54%
77%
36% 19%
13%4%
31%
4% 7%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Primary Exclusive Recurrence1 Recurrence2 Recurrence3 Recurrence4
Progression
Stable
PartialresponseCompleteresponse
2%
28% 31%42%
25%15%17%
36%42%
44%71%
54%
77%
36% 19%
13%4%
31%
4% 7%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Primary Exclusive Recurrence1 Recurrence2 Recurrence3 Recurrence4
Progression
Stable
PartialresponseCompleteresponse
2%
28% 31%42%
25%15%17%
36%42%
44%71%
54%
77%
36% 19%
13%4%
31%
4% 7%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Primary Exclusive Recurrence1 Recurrence2 Recurrence3 Recurrence4
Progression
Stable
PartialresponseCompleteresponse
TumorresponseProgression-free
survival
Median:6.2months
RYTHMIC:Exclusive(first-line)chemotherapy
Specificities- Thymic origin- Complexhistology- Auto-immunity- Staging 2016
Tumeurs thymiques
- Surgery- Postoperativeradiotherapy
Resectabletumors
Unresectabletumors
- Primarychemotherapy- Surgery- postoperativetreatment
- Definitiveradiotherapy
Metastatictumors
- First-linechemotherapy- Recurrences:
- second-linetreatment
Surgeryforrecurrences
Bae etal.JThorac Oncol 2012;7:1304
Surgeryforrecurrences
Second-linechemotherapyandbeyond
GirardN.ASCO2012EducationalBook
Second-linetreatmentofTumeurs thymiques
Thymoma
Thymiccarcinoma
Thymoma
Thymic carcinoma
0%20%40%60%80%
100%Progression
Stabledisease
Objectiveresponse
PFS(months)
0 2 4 6 8 10 12 14
PemetrexedCAP-GEMSUNITINIBOctreotideEverolimusAmrubicine
PemetrexedCAP-GEMSUNITINIBOctreotideEverolimusAmrubicine
Seconde ligne etplus
GirardN.ASCO2012EducationalBook
Enpratique:
Carbo-Px,PE,Pemetrexed
re-administrationduCAP(PS=0/1,réponse antérieure,rechute tardive;max.8cycles)
CarboplatinPaclitaxel
38%
Paclitaxel6%
PE11%
Etoposide16%
CAP12%
Adriamycin2%
CapecitabineGemcitabine
4%
Pemetrexed4% Other
7%
Chemotherapy
n=114
Targetedagents
n=67
Proposed regimens
Sunitinib47%
Sorafenib3%
Bevacizumab15%
Somatostatine
12%
Milciclib*8%
Lucitanib*4%
Everolimus11%
RYTHMIC:Systemictreatmentsforrecurrence
RYTHMIC:Systemictreatmentsforrecurrence
Administered regimens
Paclitaxel+/-
Carboplatin44%
Etoposide+Platin
16%
Etoposide4%
CAP13%
Sunitinib/Lu…
Pemetrexed3%
Milciclib3%
Others6%
Firstrecurrence
n=79
Sunitinib/other…
Paclitaxel+/-
Carbopl…
Etoposide12%
Pemetr…
Others…
Recurrence 2
n=54
Recurrence 3
n=29
Recurrence 4
n=13
Sunitinib/other
VEGF…
Paclitaxel+/-Platin…
Pemetrexed…
Everolimus7%
Others28%
Everolimus…
Sunitinib16%
Etoposide+…
Pemetrexed…
Others
31%
2%28% 31% 42%
25% 15%17%
36%42%
44% 71%
54%77%
36% 19%13% 4%
31%4% 7%
0%10%20%30%40%50%60%70%80%90%
100%
2%
28% 31%42%
25%15%17%
36%42%
44%71%
54%
77%
36% 19%
13%4%
31%
4% 7%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Primary Exclusive Recurrence1 Recurrence2 Recurrence3 Recurrence4
Progression
Stable
PartialresponseCompleteresponse
n=91n=41n=79n=64n=29 n=13
RYTHMIC:Systemictreatmentsforrecurrence
Specificities- Thymic origin- Complexhistology- Auto-immunity- Staging 2016
Tumeurs thymiques
- Surgery- Postoperativeradiotherapy
Resectabletumors
Unresectabletumors
- Biopsy- Primarychemotherapy- Surgery- postoperativetreatment
- Definitiveradiotherapy
Metastatictumors
- First-linechemotherapy- Recurrences:
- second-linetreatment- Targetedagents
• About50%ofthymomas doexpresshighlevelsofsomatostatin receptorsat111In-DTPA-octreotide(OctreoScan®)
• Responseratesarehigherinthymoma vs.thymic carcinoma:
Palmieri etal.Cancer2002;94:1414;Loehrer etal.JClin Oncol 2004;22:293Schalke B,etal.JClin Oncol 2012;30(suppl;abstr 7105)
Octreotide
Corticoids Thymoma Thymic carcinoman CR+PR SD n CR+PR SD
Palmieri,2002 + 10 4 4 3 1 1Loehrer,2004 +/- 32 12 11 5 0 3Schalke,ASCO2012 + 17 15 0 0 0 0
Specificities- Thymic origin- Complexhistology- Auto-immunity- Staging 2016
Tumeurs thymiques
- Surgery- Postoperativeradiotherapy
Resectabletumors
Unresectabletumors
- Biopsy- Primarychemotherapy- Surgery- postoperativetreatment
- Definitiveradiotherapy
Metastatictumors
- First-linechemotherapy- Recurrences:
- second-linetreatment- Targetedagents
• Overexpression:- collectively20%of501tumors- correlationwithhistologic type:
- 2%ofthymomas- vs. 87%ofcarcinomas(p=0.003)
- diagnosticbiomarkerforthymiccarcinoma
• Mutations: - 11%ofthymic carcinomas(14/129tested)
KITandthymictumors
Zucali et al. 107 4 (3%) 6 13 (46%)
Mutation Exon
E490K 9Y553N 11W557R 11V559A 11V560del 11L576P 11P577-D579del 11D579del 11H697Y 14D820E 17
Sensitivity toKITinhibitorsImatinibSunitinibSorafenib
• Expressionofangiogenesis-relatedbiomarkers- increasednumberofcellsexpressingVEGF-A,-C,-D,andVEGFR-1,-2- increasedserumlevelsofVEGFinthymic carcinomas
Neoangiogenesis
Cimpean etal.AnnAnat 2008;190:238;Sasakietal.Surg Today2001;31:1038;MarinoetPiantelli.ThorSurg Clin 2011;21:33
LancetOncol 2016;16:177
Thymic carcinomaSSP : 7,6 mois
ThymomaSSP : 6,7 mois
KIT wild-typetumors
Specificities- Thymic origin- Complexhistology- Auto-immunity- Staging 2016
Tumeurs thymiques
- Surgery- Postoperativeradiotherapy
Resectabletumors
Unresectabletumors
- Biopsy- Primarychemotherapy- Surgery- postoperativetreatment
- Definitiveradiotherapy
Metastatictumors
- First-linechemotherapy- Recurrences:
- second-linetreatment- Targetedagents
PhaseItrials
21patients
DCR=60%withmTORinhibitors
n=10
Oncotarget2013;4:890
PhaseItrials
Median:11.6months
Median:2.3months
[TITLE]
ASCO2014:everolimus
[TITLE]
ASCO2014:everolimus
Specificities- Thymic origin- Complexhistology- Auto-immunity- Staging 2016
Tumeurs thymiques
- Surgery- Postoperativeradiotherapy
Resectabletumors
Unresectabletumors
- Biopsy- Primarychemotherapy- Surgery- postoperativetreatment
- Definitiveradiotherapy
Metastatictumors
- First-linechemotherapy- Recurrences:
- second-linetreatment- Targetedagents
Initiatives&Opportunities
Specificities- Thymic origin- Complexhistology- Auto-immunity- Staging 2016
Tumeurs thymiques
- Surgery- Postoperativeradiotherapy
Resectabletumors
Unresectabletumors
- Biopsy- Primarychemotherapy- Surgery- postoperativetreatment
- Definitiveradiotherapy
Metastatictumors
- First-linechemotherapy- Recurrences:
- second-linetreatment- Targetedagents
Initiatives&Opportunities- ITMIG:databases
ITMIGDatabases:website is ccehub.org
Specificities- Thymic origin- Complexhistology- Auto-immunity- Staging 2016
Tumeurs thymiques
- Surgery- Postoperativeradiotherapy
Resectabletumors
Unresectabletumors
- Biopsy- Primarychemotherapy- Surgery- postoperativetreatment
- Definitiveradiotherapy
Metastatictumors
- First-linechemotherapy- Recurrences:
- second-linetreatment- Targetedagents
Initiatives&Opportunities- ITMIG:databases- ETOP/EORTC:translationalmedicine
Targetingimmunecheckpoints?
Giaconne.ASCO2014
Pembrolizumab phaseIItrial(NCI,GGiaccone)
TATcongress 2016
EORTC-ETOPNIVOTHYM:B3andcarcinomasStudy&design&–&open&label&phase&II&&
with&a&close&monitor&of&toxicity&for&the&first&10&pa=ents&
Stra=fica=on&factors&• !Histology!(squamous!vs!non1sq!vs!small!cell)!
• !Previous!RT!(yes!versus!no)!• !Best!response!to!first!line!treatment!(PR!vs!SD!vs!PD)!
• !Center!
Primary&endpoint:&PFS&at&6&months&Secondary&endpoints:&TTP,!Response,!!
! !!!!!!!Dura@on!of!response,!OS!
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!QOL,!Safety!&
Eligible&pa=ents&SecondCline& Nivolumab&3&mg/kg&IV&q2&weeks&&
Primary&objec=ve:&To!detect!ac@vity!of!nivolumab!as!single!agent!versus!the!best!inves@gator’s!choice!as!second!line!treatment!for!thymic!malignancies!
Biomarkers&&
PDCL1&at&baseline&and&PD&Others:&immune&paQerns,&&
molecular&profile&!
50!pa@ents!!
Courtesy JMenis
Specificities- Thymic origin- Complexhistology- Auto-immunity- Staging 2016
Tumeurs thymiques
- Surgery- Postoperativeradiotherapy
Resectabletumors
Unresectabletumors
- Biopsy- Primarychemotherapy- Surgery- postoperativetreatment
- Definitiveradiotherapy
Metastatictumors
- First-linechemotherapy- Recurrences:
- second-linetreatment- Targetedagents
Initiatives&Opportunities- ITMIG:databases- ETOP/EORTC:translationalmedicine- RYTHMIC:Tumorboardandnetwork
Coordinator:B.BesseGustave Roussy
RYTHMIC:aregionalnetworkofexpertcenters
Prospectivedatabaseandtrials
Regionalexpertcenter
NationalPathologyPanel
Guidelines
Patients
CMEactivities
TreatingPhysician
Nationalexperttumorboard
RYTHMIC:Infrastructureofthenetwork
RCPRYTHMIC
avec imagerie partagée/équipes
Onlinevirtualtumorboard
Regional expertteams
Thoracic surgeonsMedical oncologistsRadiationoncologists
PathologistsRadiologists
PneumonologistsNeurologists
RYTHMIC:Multidisciplinarytumorboard
Diagnosis/
Imaging Surgery?
PrimaryChemotherapy? Definitive Radiotherapy?
UpfrontSurgery? Post-operativeRadio
therapy?
Follow-up?
Initialmanagement
ExclusiveChemotherapy?
Post-operativeChemotherapy?
- 1000patients:1401questionsraisedatthemulti-disciplinarytumorboard
n=149(11%) n=45(3%)
n=182(13%)
n=82(6%)
n=28(2%)
n=37(3%)
n=494(35%)
n=104(7%)
n=5(0%)Surgery?
Radiotherapy?
Chemotherapy?
Targetedagent?
n=17(1%)
n=30(2%)
Diagnosis?n=47(3%)
n=67(5%)
n=114(8%)
Recurrences
Specificities- Thymic origin- Complexhistology- Auto-immunity- Staging 2016
Tumeurs thymiques
- Surgery- Postoperativeradiotherapy
Resectabletumors
Unresectabletumors
- Biopsy- Primarychemotherapy- Surgery- postoperativetreatment
- Definitiveradiotherapy
Metastatictumors
- First-linechemotherapy- Recurrences:
- second-linetreatment- Targetedagents
Initiatives&Opportunities- ITMIG:databases- ETOP/EORTC:translationalmedicine- RYTHMIC:Tumorboardandnetwork
Specificities- Thymic origin- Complexhistology- Auto-immunity- Staging 2016
Tumeurs thymiques
- Surgery- Postoperativeradiotherapy
Resectabletumors
Unresectabletumors
- Biopsy- Primarychemotherapy- Surgery- postoperativetreatment
- Definitiveradiotherapy
Metastatictumors
- First-linechemotherapy- Recurrences:
- second-linetreatment- Targetedagents
Initiatives&Opportunities- ITMIG:databases- ETOP/EORTC:translationalmedicine- RYTHMIC:Tumorboardandnetwork
Thankyou!
www.rythmic.org